Fortitude Advisory Group’s Metagenomi Therapeutics MGX Stock Holding History

Fortitude Advisory Group’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.3K	Hold	37,190	–	–	0.02%	237
2026 Q1	$49.8K	Sell	37,190 -1,550	-4%	-$2.41K	0.02%	223
2025 Q4	$62.8K	Hold	38,740	–	–	0.03%	215
2025 Q3	$91.8K	Buy	38,740 +250	+0.6%	+$507	0.05%	212
2025 Q2	$57K	Buy	38,490 +1,700	+5%	+$2.66K	0.03%	214
2025 Q1	$54.4K	Sell	36,790 -38,950	-51%	-$92.8K	0.04%	201
2024 Q4	$273K	Buy	+75,740	New	+$183K	0.16%	134

Other funds holding MGX

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

MAM

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Fortitude Advisory Group's MGX Position: Q2 2026 in Review

Fortitude Advisory Group held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 37,190 shares worth $44.3K. The position accounts for 0.02% of the portfolio, ranked #237.

Fortitude Advisory Group first reported a position in MGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $273K in Q4 2024. 3 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Fortitude Advisory Group held 37,190 shares of Metagenomi Therapeutics worth $44.3K as of Q2 2026.
Fortitude Advisory Group left its Metagenomi Therapeutics share count unchanged in Q2 2026.
Metagenomi Therapeutics made up 0.02% of Fortitude Advisory Group's portfolio in Q2 2026, its #237 holding.
Fortitude Advisory Group first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 7 quarters since.
Fortitude Advisory Group's Metagenomi Therapeutics position peaked at $273K in Q4 2024.
3 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Fortitude Advisory Group's 13F filing for Q2 2026, filed 22 Jul 2026.